Artelo enters up to $50M equity purchase facility with Square Gate; issues 292K commitment shares

ARTELO BIOSCIENCES, INC.

Equity Purchase Agreement with Square Gate provides up to $25M initially, expandable to $50M at company's option.
Company issued 292,398 commitment shares valued at $500,000 to Square Gate as consideration.
Purchase price set at 95% of lowest VWAP during valuation period (Regular Put) or lowest traded price (Intraday Put).
Regular Put capped at $500K or 30% of daily volume; Intraday Put limited to 4.99% of outstanding shares.
Registration statement must be filed within 30 days; facility runs until Jan 2029 or earlier termination.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ARTELO BIOSCIENCES, INC. entered into Equity Purchase Agreement with Square Gate Capital Master Fund, LLC – Series 5 valued at up to $25 million (effective 2026-01-30).

Action: entry
Agreement: equity purchase
Counterparty: Square Gate Capital Master Fund, LLC – Series 5
Value: up to $25 million
Effective: 2026-01-30

Exact text from the filing

On January 30, 2026, Artelo Biosciences, Inc. (the “Company”) entered into an Equity Purchase Agreement, dated as of January 30, 2026 (the “Purchase Agreement”), with Square Gate Capital Master Fund, LLC – Series 5, a series limited liability company organized in the state of Delaware (“Square Gate”), pursuant to which the Company has the right, but not the obligation, to direct Square Gate to purchase up to $25 million (the “Initial Commitment Amount”) in shares of common stock

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

ARTELO BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001640334-26-000227

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.